Grünenthal Meds
Christoph Stolle is an accomplished executive with extensive experience in the pharmaceutical industry, currently serving as Chief Integration Officer for Valinor Pharma US at Grünenthal Group and Chief Executive Officer of Grünenthal Meds, a joint venture with Kyowa Kirin International. Stolle has held various leadership roles at Grünenthal Group, including Head of Joint Venture Preparation and Senior Vice President Commercial Development for Europe and Australia. Previous positions also include General Manager of Grünenthal Spain and Commercial Director for Grünenthal Portugal. Stolle's educational background includes a Dipl. Betriebswirt in Economics from ESB Business School and a BA in European Business Administration from Middlesex University.
This person is not in any offices
Grünenthal Meds
1 followers
Grünenthal Meds was established in August 2023, as part of a Joint Venture Collaboration between Grünenthal and Kyowa Kirin. Headquartered in the UK, we are responsible for managing a portfolio of 13 medicines across six key therapeutic areas, including cancer pain, constipation, and bone health. Through a network of affiliates and key partners, we are bringing these important products to patients in need around the globe.